Is the Key to Boosting Public Transit Ridership Fare-Free Models or High-Quality, Low-Cost Models?

 

Cities worldwide are facing the challenge of traffic congestion and the need for sustainable transit solutions, turning back to the persistent challenge of boosting public transit ridership. The burning question is, what’s the right model for encouraging public transit usage in today’s transportation landscape? Some cities, such as Boston and Kansas City, are exploring fare-free public transit solutions, while others push for low-cost, high-quality options.

Fare-free transit experiments, fueled by federal COVID-19 relief funds, have demonstrated mixed results. Although they aided low-income families and slightly increased ridership, they introduced new economic and political obstacles for transit agencies. Most U.S. voters anticipate fare collection to fund a part of operating budgets, and past experiences reveal that transit riders tend to favor better, low-cost service over free rides on subpar options.

So, what is the right model to effectively boost public transit ridership while addressing these challenges? Paulo Santos, CEO of Ubirider, suggests that establishing a seamless payment system and prioritizing the quality of stops, stations, and vehicles could be the key to a successful public transit model.

 

Paulo’s Thoughts:

“With more and more people moving to urban areas, mass trans has become even a more important tool to the outside development of those areas, economically, socially, environmentally, and also to do a better use of the land available. The discussion about if transit shall be with free rides or low cost rides is very limited because what it is necessary is to design a system that attracts as many riders as possible.

And shall be designed for all with a well-designed network with a good frequency. With good quality the stops and stations and the vehicles, and to have a seamless payment system that allows to people to ride in a simple, way. So the discussion about also the investment is a discussion that is also very limited because what it is spent in public investment in roads, in parking, in speedways can be much cheaper if invest or much more valued if invest in transit.”

 

Article written by Azam Saghir.

Follow us on social media for the latest updates in B2B!

Image

Latest

AMAG Technology
AMAG Technology: Control, Reliability, and Customer-First Supply Chain Excellence
April 2, 2025

At AMAG Technology, being customer-obsessed goes beyond a mindset—it’s built into every part of the operation. One of the company’s greatest strengths lies in its ability to manufacture its own products, offering a level of supply chain control that few competitors can match. Allan Price, Head of Global Supply Chain at AMAG, emphasizes how this…

Read More
visitor management solution
Reinventing Visitor Management Solution with Symmetry GUEST
April 2, 2025

In an age where speed and security are paramount, the traditional paper logbook is becoming a relic of the past. AMAG Technology’s Symmetry Guest system offers a modern, digital solution that redefines the way organizations welcome and manage visitors. Gone are the days of long lines and confusion at the front desk—Symmetry Guest empowers hosts…

Read More
AMAG
Driven by Customers, Defined by Innovation: Inside AMAG’s Customer-Obsessed Approach
April 2, 2025

AMAG Technology continues to strengthen its customer-obsessed culture by actively listening to both internal and external voices. As shared by Kyle Gordon, Executive Vice President of Global Sales, Marketing, & Commercial Excellence, the company is focused on improving processes, responding with speed, and driving innovation—while honoring its legacy and delivering unique value within the industry.

Read More
biotech
Biotech Moves Smarter: IDDI Powers Data-Driven Drug Innovation
April 2, 2025

As biotech innovation accelerates, small and mid-size pharmaceutical companies are becoming key players in bringing new treatments to market. Yet many of these organizations face steep challenges when navigating clinical trial design, regulatory approval, and data integrity. According to a McKinsey Global Institute report, industries like biotech could help generate up to $50 trillion…

Read More